Related Experiment Videos
[Angiotensin converting enzyme inhibitors and ischemic heart diseases]
1Hôpital de Rangueil, Toulouse.
Insights
Converting enzyme inhibitors benefit patients with post-infarction left ventricular dysfunction by reducing major coronary artery disease events. These inhibitors also decrease reinfarction and unstable angina risks, showing significant cardiovascular protective effects.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Context:
- Angiotensin II plays a key role in ventricular and vascular remodeling and atherogenesis.
- Experimental and clinical studies highlight the significance of angiotensin II in cardiovascular disease progression.
Purpose:
- To evaluate the impact of converting enzyme inhibitors on cardiovascular outcomes.
- To analyze the effects of these inhibitors on mortality, morbidity, and specific cardiovascular events.
Summary:
- Converting enzyme inhibitors demonstrate beneficial effects in post-infarction left ventricular dysfunction.
- They reduce intimal thickening, smooth muscle cell proliferation, and vascular fibrosis.
- These agents may stabilize atheromatous plaques, prevent platelet aggregation, and activate fibrinolytic systems, potentially acting as nitric oxide donors.
Impact:
- Large clinical trials show a 23% reduction in reinfarction risk and a 15% reduction in unstable angina risk.
- Ongoing trials are investigating their role in coronary artery disease patients without heart failure.
- Converting enzyme inhibitors offer significant benefits for major coronary artery disease events and patient prognosis.
Abstract:
Experimental studies and molecular biological techniques have demonstrated the importance of angiotensin II in ventricular and vascular remodelling and in atherogenesis. Large scale clinical trials analysing the effects of converting enzyme inhibitors on the mortality and morbidity in post-infarction left ventricular dysfunction, have shown beneficial effects of these agents on major events of coronary artery disease. Experimental studies have shown reduction of intimal thickening and of the multiplication and migration of smooth muscle cells and of vascular fibrosis. Converting enzyme inhibitors seem to restore endothelial function by acting as donors of NO and could play a role in the stabilisation of atheromatous plaque, the prevention of platelet aggregation and on the activation of intravascular fibrinolytic systems. Large scale clinical trials (SOLVD and the prevention and treatment arms of SAVE) have also shown a 23% reduction in the risk of reinfarction and a 15% reduction in the risk of unstable angina. The results of ongoing trials in patients with coronary artery disease without cardiac failure are awaited with great impatience.